IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	David J. Grainger et al.	Examiner:	Joseph F. Murphy, Ph.D.
Serial No.:	09/150,813	Group Art Unit:	1646
Filed:	September 11, 1998	Docket:	1543.002US1
Title:	COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE		

RESPONSE

BOX AF
Commissioner for Patents
Washington, D.C. 20231

In response to the Advisory Action mailed 28 January 2002, please amend the above-identified patent application as follows.

This response is accompanied by a Petition, as well as the appropriate fee, to obtain a three-month extension of the period for responding to the Office action, thereby moving the deadline for response from November 10, 2001 to February 10, 2002.

IN THE CLAIMS

Please cancel claims 17, 20, 22, 34, 41-44 and 52-62, and add new claims 63-74. The specific amendments to individual claims are as follows:

17. (Cancel) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of a peptide of a chemokine, a variant thereof, a derivative thereof, or a combination thereof, wherein the peptide comprises no more than 30 amino acid residues, wherein the peptide comprises residues X_1-Asp-Pro-X_2-X_3-X_4-Trp-X_5-Gln or consists of X_2-X_3-X_4 or Trp-X_5-Gln, wherein X_1 is Ala or Leu, X_2 is Lys, Ser or Thr, X_4 is Lys, Glu, Ser or Arg, X_5 is Val or Ile, and X_3 is any amino acid, and wherein the peptide inhibits the response induced by at least one native chemokine, wherein the chemokine is not interleukin 8 (IL-8) or neutrophil activating protein-2 (NAP-2).

20. (Cancel) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted